Anest. intenziv. Med. 2015;26(5):270-278

Comparison of heparin and citrate anticoagulation during continuous veno-venous haemodialysis (CVVHD) in critically ill children - prospective, crossover studyIntensive Care Medicine - Original Paper

T. Zaoral1,*, M. Hladík1, J. Zapletalová2
1 Dětská klinika, Oddělení dětské intenzivní resuscitační péče, Lékařská fakulta OU, Fakultní nemocnice Ostrava
2 Ústav lékařské biofyziky, Lékařská fakulta, Fakultní nemocnice Olomouc

Objective:
In continuous renal replacement therapy, heparin anticoagulation has been largely replaced with citrate anticoagulation to limit the risk of bleeding. In this prospective crossover trial, we compared the heparin and citrate effect on the circuit lifetimes during continuous veno-venous haemodialysis (CVVHD) in children.

Design:
Prospective, crossover trial.


Setting:
Paediatric intensive care unit, Department of Paediatrics, University Hospital.

Materials and methods:
From 2009 to 2014, 63 eligible children (age 89.24 ± 62.9 months, weight 30.37 ± 20.62 kg) received at least 24 hours of CVVHD. Each child received four CVVHD circuits with anticoagulants in the following order: heparin, citrate, heparin, citrate. Circuit life ended when the trans-membrane pressure was ≥ 250 mmHg for > 60 min.

Results:
The total mean circuit lifetime was 39.75 ± 10.73 h. Citrate had a significantly longer median circuit lifetime (41.0 h, CI: 37.6-44.4) than heparin (36.0 h, CI: 35.4-36.6; p < 0.0001). Mortality was 33.33%. Circuit lifetime was significantly correlated to patient age (r = 0.606), weight (r = 0.763), and blood flow rate (r = 0.697). Metabolic and electrolyte imbalances were readily resolved.

Conclusion:
We showed that citrate provided significantly longer circuit lifetimes than heparin for CVVHD in children. Citrate was found to be feasible and safe in children and infants in our study.

Keywords: continuous venovenous hemodialysis; heparin; citrate; children

Received: March 10, 2015; Accepted: July 22, 2015; Published: October 1, 2015  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Zaoral T, Hladík M, Zapletalová J. Comparison of heparin and citrate anticoagulation during continuous veno-venous haemodialysis (CVVHD) in critically ill children - prospective, crossover study. Anest. intenziv. Med. 2015;26(5):270-278.
Download citation

References

  1. Monchi, M., Berghmans, D., Ledoux, D. et al. Citrate vs. heparin for anticoagulation in continuous venovenous hemofiltration: a prospective randomized study. Intensive Care Med., 2004, 30, p. 260-265. Go to original source... Go to PubMed...
  2. Betjes, M. G., van Oosterom, D., van Agteren, M., van de W. J.Regional citrate versus heparin anticoagulation during venovenous hemofiltration in patiens at low risk for bleeding: simile hemofilter survival but significantly less bleeding. Journal of Nephrology, 2007, 20,; p. 602-608. Go to PubMed...
  3. Kutsogiannis, D., Gibney, R., Stollery, D., Gao, J. Regional citrate versus systemic heparin anticoagulation for continuous renal replacement in critically ill patients. Kidney International, 2005, 67, 6, p. 2361-2367. Go to original source... Go to PubMed...
  4. Wu, M. Y., Hsu, Y. H., Bai, CH., Lin, Y. F. et al. Regional citrate versus heparin anticoagulation for continuous renal replacement therapy: a meta-analysis of randomized controlled trials. American Journal of Kidney Disease, 2012, 59, 6, p. 810-818. Go to original source... Go to PubMed...
  5. Brophy, P., Somers, M., Baum, M., Symons, J. M., McAfee, N.Multi-centre evaluation of anticoagulation in patiens receiving continuous renal replacement therapy (CRRT). Nephrology Dialysis Transplantation, 2005, 20, p. 1416-1421. Go to original source... Go to PubMed...
  6. Soltysiak, J., Warzywoda, A., Kociński, B. et al. Citrate anticoagulation for continuous renal replacement. Pediatric Nephrology, 2014, 29, p. 469-475. Go to original source... Go to PubMed...
  7. Fernández, S., Santiago, M., López-Herce, J., García, M., Del Castillo, J. et al. Citrate anticoagulation for CRRT in children: comparison with heparin. Biomed. Reearch International., Epub 2014, Aug 3, p. 1-7.
  8. Akcan-Arikan, A1., Zappitelli, M., Loftis, L. et al. Modified RIFLE criteria in critically ill children with acute kidney injury. Kidney International, 2007, 71, 10, p. 1028-1035. Go to original source... Go to PubMed...
  9. Akcan-Arikan, A1., Zappitelli, M., Goldstein, S. L. et al. Fluid overload is associated with impaired oxygenation and morbidity in critically ill children. Pediatr. Crit. Care Med., 2012, 13, p. 253-258. Go to original source... Go to PubMed...
  10. Goldstein, B., Giroir, B., Randolph, A. Members of the International Consensus Conference Panel (2005) International pediatric sepsis consensus conference: definitions for sepsis and organ dysfunction in pediatrics. Pediatr. Crit. Care Med., 2005, 6, p. 2-8. Go to original source... Go to PubMed...
  11. Stefanidis, I., Hägel, J. et al. Hemostatic alterations during continuous venovenous hemofiltration in acute renal failure. Clinical Nephrology, 1996, 46, 3, p. 199-205.
  12. Chadha, V., Garg, U.,Warady, B., Alon, U. Citrate clearance in children receiving continuous venovenous renal replacement therapy. Pediatric Nephrology, 2002, 17, p. 819-824. Go to original source... Go to PubMed...
  13. Gabutti, L., Marone, C. Citrate anticoagulation in continuous venovenous hemodiafiltration: a metabolic challenge. Intensive Care Medicine, 2002, 28, p. 1419-1425. Go to original source... Go to PubMed...
  14. Sohn, Y. B., Paik, K. H., Cho, H. Y., Kim, S. J., Park, S. W. et al.Continuous renal replacement therapy in neonates weighting less than 3kg. Korean Journal of Pediatrics, 2012, 55, 8, p. 286-292. Go to original source... Go to PubMed...
  15. Goldstein, S. L. Advances in pediatric renal replacement therapy for acute kidney injury. Seminars in Dialysis, 2011, 24, p. 187-191. Go to original source... Go to PubMed...
  16. Mehta, R. L., McDonald, B. R. et al. Regional citrate anticoagulation for continuous arteriovenous hemodialysis in critically ill patients. Kidney International, 1990, 38, p. 976-981. Go to original source... Go to PubMed...
  17. Moghal, N. E., Brocklebank, J. T., Meadow, S. R. A review of acute renal failure in children: incidence, etiology and outcome. Clinical Nephrology, 1998, 49, p. 91-95.
  18. Bailey, D., Phan, V., Litalien, C. et al. Risk factors of acute renal failure in critically ill children: A prospective descriptive epidemiological study. Pediatr. Crit. Care Med., 2007, 8, p. 29-35. Go to original source... Go to PubMed...
  19. Pedersen, O., Jepsen, S. B., Toft, P. Continuous renal replacement therapy for critically ill infants and children. Danish Medical Journal, 2012, 59, 2, A4385.
  20. Kramer, L., Bauer, E., Joukhadar, C. et al. Citrate pharmacokinetics and metabolism in cirrhotic and noncirrhotic critically ill patients. Crit. Care Med., 2003, 31, p. 2450-2455. Go to original source... Go to PubMed...




Anesteziologie a intenzivní medicína

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.